Johnson & JohnsonvsPuma Biotechnology

JNJ and PBYI stock compared: price, dividend, valuation and results, from SEC filings.

PBYI

Puma Biotechnology Inc

$7.10

Value $361M

-0.28%
PBYI's page

Johnson & Johnson (JNJ) has a market value of $653B and Puma Biotechnology (PBYI) $361M. Over the last year, with dividends, JNJ moved +36.7% and PBYI +45.2%. The P/E is 40.5 for JNJ and 15.2 for PBYI. Dividend yield: JNJ 1.95%, PBYI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$653B

    PBYI$361M

    JNJ is 1,807 times PBYI

  • Revenue, 12 months

    JNJ$99.3B

    PBYI$232M

    JNJ is 428 times PBYI

  • Net income, 12 months

    JNJ$16.1B

    PBYI$24M

    JNJ is 675 times PBYI

  • Operating margin

    JNJ–

    PBYI11.3%

  • ROIC

    JNJ12.4%

    PBYI12.8%

    0.4 points apart

  • P/E

    JNJ40.5

    PBYI15.2

    JNJ is 2.7 times PBYI

  • Dividend yield

    JNJ2.0%

    PBYI0.0%

    2.0 points apart

  • 5-year return

    JNJ+91.1%

    PBYI+107.6%

    16.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+91.1%

PBYI+107.6%

10020030020222023202420252026
Returns by period
PeriodJNJWith dividendsPBYIWith dividends
1 year since November 19, 2025+36.7%Price +33.7%+45.2%Price +45.2%
3 years since November 20, 2023+95.1%+25.0% a yearPrice +80.6%+82.5%+22.2% a yearPrice +82.5%
5 years since November 19, 2021+91.1%+13.8% a yearPrice +66.2%+107.6%+15.7% a yearPrice +107.6%
10 years since November 21, 2016+206.8%+11.9% a yearPrice +135.5%-83.8%-16.6% a yearPrice -83.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPBYIPuma Biotechnology

Valuation

JNJPBYI
Valuation
Price$270.78$7.10
Market value$653B$361M
Enterprise value (EV)$680B$306M
P/E40.515.2
P/E, 5-year median21.99.6
P/B8.02.5
EV/EBIT38.311.7
Free cash flow yield3.2%12.7%

Results and growth

JNJPBYI
Results and growth
Revenue, 12 months$99.3B$232M
Net income, 12 months$16.1B$24M
Free cash flow, 12 months$20.6B$46M
Earnings per share, 12 months$6.59$0.46
Revenue growth, year on year6.1%-0.9%
Revenue growth a year, past+2.7%over 5 years+0.3%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJPBYI
Margins and returns on capital
Gross margin67.6%73.6%
Operating margin–11.3%
Net margin16.2%10.3%
ROIC12.4%12.8%
ROE19.7%18.1%

Balance sheet

JNJPBYI
Balance sheet
Cash$17.2B$101M
Total debt$44.7B$50M
Net debt / EBITDA1.1-1.5
Interest cover18.0×12.9×

Dividends and buybacks

JNJPBYI
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PBYI

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Puma Biotechnology?

By market value, Johnson & Johnson ($653B) is about 1,806.5 times Puma Biotechnology ($361M), at today's prices.

How did JNJ and PBYI stock do over the last 10 years?

Since November 21, 2016, JNJ's price moved +135.5% and PBYI's -83.8%. With dividends: JNJ +206.8% (+11.9% a year), PBYI -83.8% (-16.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PBYI?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Puma Biotechnology. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and PBYI?

At today's price, the P/E is 40.5 for JNJ and 15.2 for PBYI. The median of the last five years was 21.9 and 9.6, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Puma Biotechnology?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 10.3% for Puma Biotechnology, and the operating margin – and 11.3%. Revenue was $99.3B and $232M.

Which is the better investment, Johnson & Johnson or Puma Biotechnology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.